Smoking medical therapy: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) |
Usama Talib (talk | contribs) |
||
Line 48: | Line 48: | ||
|} | |} | ||
===Pharmacological=== | ===Pharmacological Therapy=== | ||
First-line pharmacotherapy includes the multiple forms of nicotine replacement therapy (patch, nasal spray, losenge, gum, inhaler), sustained- release [[Bupropion extended release|bupropion]] hydrochloride, and [[varenicline]]. Second line therapy includes [[clonidine]] and [[nortriptyline]] and have been found to be efficacious.<ref name="urlwww.vapremier.com">{{cite web |url=https://www.vapremier.com/assets/SmokingCessationGuideline.pdf |title=www.vapremier.com |format= |work= |accessdate=}}</ref><br> | First-line pharmacotherapy includes the multiple forms of nicotine replacement therapy (patch, nasal spray, losenge, gum, inhaler), sustained- release [[Bupropion extended release|bupropion]] hydrochloride, and [[varenicline]]. Second line therapy includes [[clonidine]] and [[nortriptyline]] and have been found to be efficacious.<ref name="urlwww.vapremier.com">{{cite web |url=https://www.vapremier.com/assets/SmokingCessationGuideline.pdf |title=www.vapremier.com |format= |work= |accessdate=}}</ref><br> | ||
'''The following is a description of the various treatment modalities available:'''<ref name="pmid18617085">{{cite journal| author=Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff| title=A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. | journal=Am J Prev Med | year= 2008 | volume= 35 | issue= 2 | pages= 158-76 | pmid=18617085 | doi=10.1016/j.amepre.2008.04.009 | pmc=4465757 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18617085 }} </ref> | '''The following is a description of the various treatment modalities available:'''<ref name="pmid18617085">{{cite journal| author=Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff| title=A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. | journal=Am J Prev Med | year= 2008 | volume= 35 | issue= 2 | pages= 158-76 | pmid=18617085 | doi=10.1016/j.amepre.2008.04.009 | pmc=4465757 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18617085 }} </ref> |
Revision as of 16:13, 31 May 2017
Smoking Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Medical Therapy
General Principles
The 5As are an evidence-based framework for structuring smoking cessation in health care settings. The 5As include: Ask, Assess, Advise, Assist and Arrange follow-up.
|
Pharmacological Therapy
First-line pharmacotherapy includes the multiple forms of nicotine replacement therapy (patch, nasal spray, losenge, gum, inhaler), sustained- release bupropion hydrochloride, and varenicline. Second line therapy includes clonidine and nortriptyline and have been found to be efficacious.[1]
The following is a description of the various treatment modalities available:[2]
- Sustained release bupropion hydrochloride:
- Nicotine gum:
- Dose: 1–24 cigarettes/day: 2mg gum (up to 24 pieces/day). ≥ 25 cigarettes/day: 4 mg gum (up to 24 pieces/day).
- Duration: Up to 12 weeks
- Adverse effects: Mouth soreness and dyspepsia
- Nicotine inhaler:
- Dose: 6–16 cartridges/day
- Duration: Up to 6 months
- Adverse effects: Local irritation of mouth and throat
- Nicotine lozenges:
- Nicotine nasal spray:
- Dose: 8–40 doses/day
- Duration: 3–6 months
- Adverse effects: Nasal irritation
- Varenicline:
- Dose: 0.5 mg/day for 3 days followed by 0.5 mg twice/day for 4 days. Then, 1 mg twice/day
- Duration: 3–6 months
- Adverse effects: Nausea, trouble sleeping, vivid/strange dreams and depressed mood
References
- ↑ "www.vapremier.com" (PDF).
- ↑ Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff (2008). "A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report". Am J Prev Med. 35 (2): 158–76. doi:10.1016/j.amepre.2008.04.009. PMC 4465757. PMID 18617085.